“Nintedanib in children and adolescents with fibrosing interstitial lung diseases.” R. Deterding, L.R. Young, E.M. DeBoer, D. Warburton, S. Cunningham, N. Schwerk, K.R. Flaherty, K.K. Brown, M. Dumistracel, E. Erhardt, J. Bertulis, M. Gahlemann, S. Stowasser and M. Griese for the InPedILD trial investigators. Eur Respir J 2023; 61: 2201512

Due to a programming error, one patient in the age 12–17 year group was omitted from the analyses presented in this study. This resulted in incorrect data being included in supplementary table S4. Table S4 in the supplementary materials has been amended to correct this.

Furthermore, the following sentence in the Pharmacokinetics section of the Results, has been changed from: “The geometric mean (gCV) AUCτ,ss for nintedanib was 175 µg·h·L⁻¹ (85.1%) in patients aged 6–11 years and 160 µg·h·L⁻¹ (82.7%) in patients aged 12–17 years.”

to:

“The geometric mean (gCV) AUCτ,ss for nintedanib was 175 µg·h·L⁻¹ (85.1%) in patients aged 6–11 years and 167 µg·h·L⁻¹ (83.6%) in patients aged 12–17 years.”

The same correction has also been made in the appropriate place in the abstract of the article. The article has been corrected and republished online.